Skip to content

Muscle Relaxants and Laryngeal Local Anesthetics for Laryngeal Mask Airway Insertion Decreasing Propofol in Elderly

The Impact of Using Muscle Relaxants and Laryngeal Local Anesthetics for Laryngeal Mask Airway (LMA) Insertion on Hemodynamics and Induction Anesthetics Dosage in Elderly

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05310110
Acronym
LMA
Enrollment
96
Registered
2022-04-04
Start date
2022-04-12
Completion date
2023-08-24
Last updated
2024-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, General

Keywords

Muscle relaxants, Laryngeal local anesthetics, Laryngeal mask airway, Laryngeal Masks, LMA, Propofol, Elderly, Aged

Brief summary

Laryngeal mask airway (LMA) is currently the most widely used supraglottic airway device with advantages of simple and fast placement, reduced anesthesia drug use, more stable hemodynamics, and less throat discomfort after anesthesia compared to endotracheal intubation. Some studies claimed the use of muscle relaxants or local anesthetics (sprays or lubricants containing local anesthetics) for the throat before LMA placement can reduce the dosage of induction agents and postoperative throat complications. In modern society, more and more elderly people undergo elective surgery with the need of general anesthesia. However, they are the more vulnerable population with tendency of greater hemodynamic changes with more induction agent usage. Propofol is one of the most used induction agents which may lead to a drop in blood pressure. The objective of this study is to observe whether the dose of propofol and the changes in hemodynamics can be reduced by using muscle relaxants or laryngeal local anesthetics in elderly who receiving general anesthesia with LMA insertion.

Interventions

10% lidocaine spray 3 puff for the throat before induction

DRUGPlacebo of lidocaine spray

Normal saline spray 3 puff for the throat before induction

DRUGCisatracurium

Intravenous cisatracurium 0.12 mg/kg during induction

DRUGPlacebo of cisatracurium

Intravenous normal saline during induction

DRUGPropofol

The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* American Society of Anesthesiologists (ASA) physical status I-III * Age: over 65 years * Elective orthopedic surgery undergo general anesthesia in supine position

Exclusion criteria

* Anticipated difficult airway (Mallampati score 3-4), limited mouth opening, intra-oral and pharyngeal pathology * Risk of pulmonary aspiration of gastric contents (full stomach) * Obesity (Body mass index \> 35) * Significant lung abnormalities (low lung compliance, high airway resistance, impaired oxygenation) * Loosening teeth * Allergic to Cisatracurium or Lidocaine * Failure in successful LMA insertion after second attempts

Design outcomes

Primary

MeasureTime frameDescription
Propofol requirementone minute after propofol infusionThe minimal propofol requirement dose was defined as the median effective dose (ED50) of movement or increased mean arterial pressure (MAP) to no movement or stable MAP. The ED50 is the average of the crossover midpoints found during conducting the Dixon's up-and-down method.

Secondary

MeasureTime frameDescription
Heart rate (HR)0 minute, 1 minute, 2 minute, 3 minute, 4 minute, 5 minute, 10 minute after LMA placementUsing the electrocardiogram monitor to collect the real-time heart rate
Oxygen saturation (SpO2)0 minute, 1 minute, 2 minute, 3 minute, 4 minute, 5 minute, 10 minute after LMA placementUsing the pulse oximeter to collect the real-time oxygen saturation
Peak pressure (P peak) of the airway0 minute after LMA placementOne of the monitoring parameter demonstrated on the mechanical ventilator
Mean pressure (P mean) of the airway0 minute after LMA placementOne of the monitoring parameter demonstrated on the mechanical ventilator
Ease of jaw openingProcedure (At the same time of LMA placement)A factor for evaluating the condition of LMA insertion
Ease of LMA insertionProcedure (At the same time of LMA placement)A factor for evaluating the condition of LMA insertion
Non-invasive blood pressure (NIBP)0 minute, 1 minute, 2 minute, 3 minute, 4 minute, 5 minute, 10 minute after LMA placementUsing the non-invasive blood pressure machine to collect the systolic blood pressure, diastolic blood pressure, and mean arterial pressure
HiccupsWithin 1 minute after LMA placementSymptoms which suggest non-optimal condition of LMA insertion
Head or body movementWithin 1 minute after LMA placementSymptoms which suggest non-optimal condition of LMA insertion
LaryngospasmWithin 1 minute after LMA placementLaryngospasm is defined as airway obstruction with assumption that LMA is correctly placed, which is also a factor for evaluating the condition of LMA insertion
Attempts for LMA insertionProcedure (At the same time of LMA placement)The number of attempts for LMA insertion
ComplicationsOne hour after LMA removalIncluding sore throat, dysphagia, dysphonia
Coughing or gaggingWithin 1 minute after LMA placementSymptoms which suggest non-optimal condition of LMA insertion

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026